TG Therapeutics, Inc. (TGTX)

Market Cap	2.83B
Revenue (ttm)	289.33M
Net Income (ttm)	41.20M
Shares Out	154.54M
EPS (ttm)	0.22
PE Ratio	83.23
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,866,327
Open	18.08
Previous Close	18.15
Day's Range	17.79 - 18.45
52-Week Range	6.46 - 26.95
Beta	2.30
Analysts	Strong Buy
Price Target	31.20 (+70.4%)
Earnings Date	Jul 30, 2024

About TGTX

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral i...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 14, 1995
• Employees: 264
• Stock Exchange: NASDAQ
• Ticker Symbol: TGTX

Analyst Forecast

According to 6 analysts, the average rating for TGTX stock is "Strong Buy." The 12-month stock price forecast is $31.2, which is an increase of 70.40% from the latest price.

Price Target

$31.2

(70.40% upside)

Analyst Consensus: Strong Buy